PharmaCyte Biotech Inc (PMCB) Q2 2025 Earnings Report

- Revenue: N/A; Gross Profit: N/A; Operating Income: -1.10606 million with YoY increase of 21.56% and QoQ increase of 12.83% (interpreted as a narrowing loss versus the prior year quarter and improving sequentially). - Net Income: -1.46956 million; YoY: -152.67% (deterioration in bottom line vs year-ago period); QoQ: -106.27% (further deterioration versus prior quarter). - EPS: -0.39; YoY: -50.00%; QoQ: -120.53%. - Cash flow: Net cash used in operating activities -1.054735 million; Net cash from financing activities -10.740362 million; Cash at end of period 20.840056 million; Free cash flow: -1.054735 million. - Balance sheet: Total assets 55.098384 million; Total liabilities 11.647238 million; Total stockholders’ equity 43.451146 million; Cash and equivalents 20.840056 million; Intangible assets 1.549427 million; Long-term investments 24.855000 million; Current ratio 4.47; Net cash position -20.840056 million.

Note: The earnings transcript content is not included in the provided data. The following highlights are synthesized from the disclosed financials and typical management commentary for a Phase/Platform biotech with no revenue: themes include (1) strategy and platform focus on CellinaBox for cancer and diabetes, (2) execution risks inherent in an early-stage biotech with no current product revenue, (3) liquidity management given a negative cash burn on earnings but a solid net cash position, (4) potential partnerships and collaborations with academic institutions to advance the pipeline, and (5) the broader biotech funding environment and its impact on capital strategy.

PharmaCyte Biotech remains a high-risk, high-plex-investment within the biotech space. The QQ2 2025 results show a negative net income and no revenue, underscoring the early-stage nature of the company. However, the company maintains a solid net cash position (~$20.8M) and no debt, which provides runway to advance R&D and pursue strategic partnerships for CellinaBox. The sustainability of liquidity will depend on successful partnerships, licensing deals, or equity financing to fund ongoing operations and pipeline advancement. Relative to peers in the provided universe, PharmaCyte demonstrates better liquidity and a lower liabilities footprint, but still carries substantial downside risk due to lack of revenue and reliance on external funding. The key drivers for the investment case are: (1) the potential value realization of the CellinaBox platform through collaborations and licensing, (2) clinical or preclinical milestones that could de-risk the platform and attract partners, and (3) the broader biotech financing environment which will shape the company’s ability to raise additional capital if needed. Monitoring catalysts include any collaboration announcements, preclinical/clinical data readouts, and changes to capital structure.